Holen Sie sich die Stockscreener-App
20.30
3.44%
0.675
Schlusskurs vom Vortag:
$19.62
Offen:
$19.86
24-Stunden-Volumen:
25,434
Relative Volume:
0.07
Marktkapitalisierung:
$838.01M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-136.98M
KGV:
-5.0485
EPS:
-4.02
Netto-Cashflow:
$-126.63M
1W Leistung:
-2.43%
1M Leistung:
-18.53%
6M Leistung:
-4.90%
1J Leistung:
-24.44%
1-Tages-Spanne:
$19.86
$20.56
1-Wochen-Bereich:
$18.20
$21.16
52-Wochen-Spanne:
$15.47
$29.71
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Firmenname
Arrivent Biopharma Inc
Sektor
Branche
Telefon
240-780-6356
Adresse
18 CAMPUS BLVD., NEWTOWN SQUARE
Vergleichen Sie AVBP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
20.30 | 809.94M | 0 | -136.98M | -126.63M | -4.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.37 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
810.29 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
814.78 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.34 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-10 | Eingeleitet | BTIG Research | Buy |
| 2025-11-25 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-03-20 | Eingeleitet | B. Riley Securities | Buy |
| 2025-03-10 | Eingeleitet | Guggenheim | Buy |
| 2024-07-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-20 | Eingeleitet | Citigroup | Buy |
| 2024-02-20 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Arrivent Biopharma Inc Aktie (AVBP) Neueste Nachrichten
Can ArriVent BioPharma Inc. stock attract ESG capital inflowsJuly 2025 Rallies & Entry Point Strategy Guides - ulpravda.ru
Will ArriVent BioPharma Inc. stock see insider buyingQuarterly Market Review & Fast Moving Stock Trade Plans - ulpravda.ru
Oppenheimer reiterates Outperform rating on ArriVent BioPharma stock By Investing.com - Investing.com Canada
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 7.4%Here's What Happened - MarketBeat
Responsive Playbooks and the AVBP Inflection - Stock Traders Daily
ArriVent BioPharma: Its Leading Asset, Furmonertinib, Supports A Cautious Buy - Seeking Alpha
Firmonertinib Trial Aims to Crack a Long-Standing Lung Cancer Treatment Gap - MyChesCo
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts (NASDAQ:AVBP) - Seeking Alpha
(AVBP) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
ArriVent BioPharma (NASDAQ:AVBP) Trading Down 3.2%What's Next? - MarketBeat
ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug - Investing.com Australia
ArriVent Biopharma initiated with an Overweight at Cantor Fitzgerald - TipRanks
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald initiates ArriVent BioPharma stock with Overweight rating - Investing.com
ArriVent Biopharma announces first patient dosed in Phase 3 ALPACCA study - TipRanks
ArriVent BioPharma Begins Phase 3 Trial of Firmonertinib in Lung Cancer - marketscreener.com
ArriVent BioPharma Initiates Pivotal Phase 3 ALPACCA Study of Firmonertinib for First-Line Treatment of EGFR PACC Mutant NSCLC - Quiver Quantitative
ArriVent doses first patient in pivotal phase 3 trial for lung cancer drug By Investing.com - Investing.com South Africa
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer - marketscreener.com
New lung cancer trial tests a daily chemo-free pill for rare mutation - Stock Titan
Investment Recap: Will ArriVent BioPharma Inc. stock benefit from AI adoptionLong Setup & Daily Profit Maximizing Tips - Улправда
Will ArriVent BioPharma Inc. stock benefit from AI adoptionQuarterly Portfolio Review & Free AI Powered Buy and Sell Recommendations - Улправда
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Will ArriVent BioPharma Inc. stock pay special dividendsTrade Volume Summary & Low Drawdown Investment Strategies - ulpravda.ru
Will ArriVent BioPharma Inc. stock remain a Wall Street favorite2025 Technical Overview & Real-Time Buy Zone Alerts - Улправда
Why ArriVent BioPharma Inc. stock is recommended by analystsMarket Trend Summary & Weekly Breakout Watchlists - Улправда
ArriVent BioPharma (NASDAQ:AVBP) Stock Price Down 5.6%Here's What Happened - MarketBeat
Will ArriVent BioPharma Inc. stock deliver consistent dividendsJuly 2025 Price Swings & AI Forecasted Entry and Exit Points - Улправда
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B (2025-12-16) - Seeking Alpha
Squarepoint Ops LLC Grows Stock Position in ArriVent BioPharma, Inc. $AVBP - MarketBeat
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B - Newswire Canada
ArriVent BioPharma Earnings Notes - Trefis
ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential - MSN
Fund 1 Investments LLC Acquires New Position in ArriVent BioPharma, Inc. $AVBP - MarketBeat
Why (AVBP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
BTIG Research Begins Coverage on ArriVent BioPharma (NASDAQ:AVBP) - Defense World
ArriVent BioPharma Inc (AVBP) is looking forward to a strong quarter - setenews.com
ArriVent BioPharma (NASDAQ:AVBP) Coverage Initiated at BTIG Research - MarketBeat
BTIG initiates coverage of ArriVent BioPharma (AVBP) with buy recommendation - MSN
ArriVent BioPharma stock initiated with Buy rating at BTIG on oncology potential - Investing.com Canada
ArriVent Biopharma initiated with a Buy at BTIG - TipRanks
BTIG Initiates ArriVent BioPharma at Buy With $45 Price Target - marketscreener.com
ArriVent BioPharma (NASDAQ:AVBP) versus Sunshine Biopharma (NASDAQ:SBFM) Critical Review - Defense World
Buy Rating for ArriVent BioPharma, Inc. Driven by Promising Developments in EGFR Exon 20 NSCLC Treatment - TipRanks
Is ArriVent BioPharma Inc (AVBP) positioned for future growth? - Setenews
Buy Rating for ArriVent BioPharma Driven by Promising Firmonertinib Trial Results - TipRanks
ArriVent BioPharma (NASDAQ:AVBP) Shares Down 6.4%Here's What Happened - MarketBeat
Understanding Momentum Shifts in (AVBP) - Stock Traders Daily
ArriVent BioPharma Taps Brent S. Rice as Chief Commercial Officer - MSN
How ArriVent BioPharma Inc. stock trades before earnings2025 Trading Volume Trends & Accurate Trade Setup Notifications - Newser
Finanzdaten der Arrivent Biopharma Inc-Aktie (AVBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):